Comparative in vitro activities of eravacycline in combination with colistin, meropenem, or ceftazidime against various Achromobacter spp. strains isolated from patients with cystic fibrosis

References

• Pickett MJ, Hollis DG, Bottone EJ, et al. Miscellaneous gram-negative bacteria. In: Manual of clinical microbiology. 5th ed. Washington (DC): American Society for Microbiology; 1991. p. 410–428.
   Google Scholar
• Steinberg JP, Del Rio C. Other gram-negative bacilli. In: Mandell GL, Bennet JE, Dolin R, editors. Principles and practice of ınfectious diseases. 7th ed. Edinburg: Churchill Livingstone; 2000. p. 2459–2474.
   Google Scholar
• Teng SO, Ou TY, Hsieh YC, et al. Complicated intra-abdominal infection caused by extended drug-resistant Achromobacter xylosoxidans. J Microbiol Immunol Infect. 2009;42(2):176–180.
   PubMedGoogle Scholar
• Duggan JM, Goldstein SJ, Chenoweth CE, et al. Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Clin Infect Dis. 1996;23(3):569–576.
   PubMed Web of Science ®Google Scholar
• Gade SS, Nørskov-Lauritsen N, Ridderberg W. Prevalence and species distribution of Achromobacter sp. cultured from cystic fibrosis patients attending the aarhus Centre in Denmark. J Med Microbiol. 2017;66(5):686–689.
   PubMed Web of Science ®Google Scholar
• Pereira RHV, Leao RS, Carvalho-Assef AP, et al. Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis. Epidemiol Infect. 2017;145(3):600–606.
   PubMed Web of Science ®Google Scholar
• Baets FD, Schelstraete P, Daele SV, et al. Achromobacter xylosoxidans infection in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros. 2007;6(1):75–78.
   PubMed Web of Science ®Google Scholar
• Behrens-Muller B, Conway J, Yoder J, et al. Investigation and control of an outbreak of Achromobacter xylosoxidans bacteremia. Infect Control Hosp Epidemiol. 2012;33(2):180–184.
   PubMed Web of Science ®Google Scholar
• Marion-Sanchez K, Pailla K, Olive C, et al. Achromobacter spp. healthcare-associated infections in the french west ındies: a longitudinal study from 2006 to 2016. BMC Infect Dis. 2019;19(1):1–10.
   PubMed Web of Science ®Google Scholar
• Gahrn-Hansen B, Alstrup P, Dessau R, et al. Outbreak of infection with Achromobacter xylosoxidans from contaminated intravascular pressure transducers. J Hosp Infect. 1988;12(1):1–6.
   PubMed Web of Science ®Google Scholar
• Amoureux L, Sauge J, Sarret B, et al. Study of 109 achromobacter spp. isolates from 9 french CF centres reveals the circulation of a multiresistant clone of A. xylosoxidans belonging to ST 137. J Cyst Fibros. 2019;18(6):804–807.
   PubMed Web of Science ®Google Scholar
• Haviari S, Cassier P, Dananché C, et al. Outbreak of Achromobacter xylosoxidans and Ochrobactrum anthropi infections after prostate biopsies, France, 2014. Emerg Infect Dis. 2016;22(8):1412–1419.
   PubMed Web of Science ®Google Scholar
• Swenson CE, Sadikot RT. Achromobacter respiratory infections. Ann Am Thorac Soc. 2015;12(2):252–258.
   PubMed Web of Science ®Google Scholar
• Schaffer K. Epidemiology of infection and current guidelines for infection prevention in cystic fibrosis patients. J Hosp Infect. 2015;89(4):309–313.
   PubMed Web of Science ®Google Scholar
• Traglia GM, Almuzara M, Merkier AK, et al. Achromobacter xylosoxidans: an emerging pathogen carrying different elements involved in horizontal genetic transfer. Curr Microbiol. 2012;65(6):673–678.
   PubMed Web of Science ®Google Scholar
• Molin S, Tolker-Nielsen T. Gene transfer occurs with enhanced efficiency in biofilms and induces enhanced stabilisation of the biofilm structure. Curr Opin Biotechnol. 2003;14(3):255–261.
   PubMed Web of Science ®Google Scholar
• Li X, Hu Y, Gong J, et al. Comparative genome characterisation of achromobacter members reveals potential genetic determinants facilitating the adaptation to a pathogenic lifestyle. Appl Microbiol Biotechnol. 2013;97(14):6413–6425.
   PubMed Web of Science ®Google Scholar
• Isler B, Kidd TJ, Stewart AG, et al. Achromobacter infections and treatment options. Antimicrob Agents Chemother. 2020;64(11):e01025-20.
   PubMed Web of Science ®Google Scholar
• Mathy V, Grohs P, Compain F. In vitro activity of β-lactams in combination with avibactam against multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Achromobacter xylosoxidans isolates from patients with cystic fibrosis. J Med Microbiol. 2018;67(9):1217–1220.
   PubMed Web of Science ®Google Scholar
• Abbott IJ, Peleg AY. Stenotrophomonas, achromobacter, and nonmelioid burkholderia species: antimicrobial resistance and therapeutic strategies. Semin Respir Crit Care Med. 2015;36(1):99–110.
   PubMed Web of Science ®Google Scholar
• Döring G, Flume P, Heijerman H, et al. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012;11(6):461–479.
   PubMed Web of Science ®Google Scholar
• Ulloa ER, Kousha A, Tsunemoto H, et al. Azithromycin exerts bactericidal activity and enhances innate immune-mediated killing of MDR Achromobacter xylosoxidans. Infect Microb Dis. 2020;2(1):10–17.
   Google Scholar
• Wang M, Ridderberg W, Hansen CR, et al. Early treatment with inhaled antibiotics postpones next occurrence of achromobacter in cystic fibrosis. J Cyst Fibros. 2013;12(6):638–643.
   PubMed Web of Science ®Google Scholar
• CLSI. Performance standards for antimicrobial susceptibility testing, M100. 31st ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2021.
   Google Scholar
• CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In: CLSI standard M07. 11th ed. Wayne (PA): Clinical and Laboratory Standards Institute; 2018.
   Google Scholar
• National Committee for Clinical Laboratory Standards. Methods for determining a bactericidal activity of antimicrobial agents: approved guideline M26-A. Wayne (PA): NCCLS; 1999.
   Google Scholar
• Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25(3):450–470.
   PubMed Web of Science ®Google Scholar
• Karageorgopoulos D, Falagas ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis. 2008;8(12):751–762.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Athanassaki F, Pitiriga V, et al. Clinical relevance of in vitro synergistic activity of antibiotics for multidrug-resistant gram-negative infections: a systematic review. J Glob Antimicrob Resist. 2019;17:250–259.
   PubMed Web of Science ®Google Scholar
• Klastersky J, Zinner ZS. Synergistic combinations of antibiotics in gram-negative bacillary ınfections. Rev Infect Dis. 1982;4(2):294–301.
   PubMedGoogle Scholar
• Pereira RHV, Carvalho-Assef AP, Albano RM, et al. Achromobacter xylosoxidans: characterisation of strains in Brazilian cystic fibrosis patients. J Clin Microbiol. 2011;49(10):3649–3651.
   PubMed Web of Science ®Google Scholar
• Spicuzza L, Sciuto C, Vitaliti G, et al. Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients. Eur J Clin Microbiol Infect Dis. 2009;28(2):191–195.
   PubMed Web of Science ®Google Scholar
• Damar-Çelik D, Nørskov-Lauritsen N, Özbek-Çelik B. Comparative in vitro activities of meropenem in combination with colistin, levofloxacin, or chloramphenicol against Achromobacter xylosoxidans strains isolated from patients with cystic fibrosis. J Glob Antimicrob Resist. 2020;22:713–717.
   PubMed Web of Science ®Google Scholar
• Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168(8):918–951.
   PubMed Web of Science ®Google Scholar
• Ozbek B, Sentürk A. Postantibiotic effects of tigecycline, colistin sulfate, and levofloxacin alone or tigecycline-colistin sulfate and tigecycline-levofloxacin combinations against Acinetobacter baumannii. Chemother. 2010;56(6):466–471.
   PubMed Web of Science ®Google Scholar
• Louie A, Grasso C, Bahniuk N, et al. The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob Agents Chemother. 2010;54(6):2646–2654.
   PubMed Web of Science ®Google Scholar
• Schimpff S, Satterlee W, Young MV, et al. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971;284(19):1061–1065.
   PubMed Web of Science ®Google Scholar
• Gaibani P, Lombardo D, Lewis RE, et al. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother. 2014;69(7):1856–1865.
   PubMed Web of Science ®Google Scholar